Krystal Biotech, Inc. announced plans to develop KB707, an immunotherapy for non-small cell lung cancer. The FDA granted an End of Phase 2 meeting in October based on promising results. In a study, 36% of NSCLC patients responded positively to inhaled KB707, with no severe side effects reported. Enrollment is ongoing for the KYANITE-1 trial while enrollment in the OPAL-1 trial has been paused. Krystal Biotech focuses on genetic medicines and is headquartered in Pittsburgh. The company continues to advance treatments for various diseases. Forward-looking statements caution about potential risks involved in the KB707 program.

Read more at GlobeNewswire: Krystal Biotech Announces Update on Development Plans for